Descriptor English: | Proto-Oncogene Proteins c-rel | ||||||
Descriptor Spanish: |
Proteínas Proto-Oncogénicas c-rel
| ||||||
Descriptor Portuguese: | Proteínas Proto-Oncogênicas c-rel | ||||||
Descriptor French: | Protéines proto-oncogènes c-rel | ||||||
Entry term(s): |
Protein, c-rel Proteins, c-rel Proto Oncogene Products c rel Proto Oncogene Protein c rel Proto Oncogene Proteins c rel Proto Oncogene Proteins rel Proto-Oncogene Products c-rel Proto-Oncogene Protein c-rel Proto-Oncogene Proteins rel Proto-Oncogene Proteins, rel c rel Protein c rel Proteins c-rel Protein c-rel Proteins c-rel, Proto-Oncogene Products c-rel, Proto-Oncogene Protein c-rel, Proto-Oncogene Proteins c-rel, p68 p68 c rel p68 c-rel p68(c-rel) rel Proto Oncogene Product p68 rel Proto Oncogene Proteins rel Proto-Oncogene Product p68 rel Proto-Oncogene Proteins |
||||||
Tree number(s): |
D12.776.260.682 D12.776.624.664.700.192 D12.776.660.767 D12.776.930.730 |
||||||
RDF Unique Identifier: | https://id.nlm.nih.gov/mesh/D020569 | ||||||
Scope note: | Cellular DNA-binding proteins encoded by the rel gene (GENES, REL). They are expressed predominately in hematopoietic cells and may play a role in lymphocyte differentiation. Rel frequently combines with other related proteins (NF-KAPPA B, I-kappa B, relA) to form heterodimers that regulate transcription. Rearrangement or overexpression of c-rel can cause tumorigenesis. |
||||||
Allowable Qualifiers: |
AD administration & dosage AE adverse effects AG agonists AI antagonists & inhibitors AN analysis BI biosynthesis BL blood CF cerebrospinal fluid CH chemistry CL classification CS chemical synthesis DE drug effects DF deficiency EC economics GE genetics HI history IM immunology IP isolation & purification ME metabolism PD pharmacology PH physiology PK pharmacokinetics PO poisoning RE radiation effects SD supply & distribution ST standards TO toxicity TU therapeutic use UL ultrastructure UR urine |
||||||
Previous Indexing: |
Proto-Oncogene Proteins (1988-1999) |
||||||
Public MeSH Note: | 2000; PROTO-ONCOGENE PROTEIN C-REL was indexed under PROTO-ONCOGENE PROTEINS 1988-1999 |
||||||
History Note: | 2000; use PROTO-ONCOGENE PROTEINS C-REL (NM) 1988-1999 |
||||||
Related: |
Genes, rel
MeSH I-kappa B Proteins MeSH | ||||||
DeCS ID: | 34473 | ||||||
Unique ID: | D020569 | ||||||
Documents indexed in the Virtual Health Library (VHL): | Click here to access the VHL documents | ||||||
Date Established: | 2000/01/01 | ||||||
Date of Entry: | 1999/11/08 | ||||||
Revision Date: | 2015/06/29 |
-
-
CHEMICALS AND DRUGS
Amino Acids, Peptides, and Proteins [D12]Amino Acids, Peptides, and Proteins -
CHEMICALS AND DRUGS
Amino Acids, Peptides, and Proteins [D12]Amino Acids, Peptides, and Proteins -
CHEMICALS AND DRUGS
Amino Acids, Peptides, and Proteins [D12]Amino Acids, Peptides, and Proteins -
CHEMICALS AND DRUGS
Amino Acids, Peptides, and Proteins [D12]Amino Acids, Peptides, and Proteins
|
Proto-Oncogene Proteins c-rel
- Preferred
Concept UI |
M0328561 |
Scope note | Cellular DNA-binding proteins encoded by the rel gene (GENES, REL). They are expressed predominately in hematopoietic cells and may play a role in lymphocyte differentiation. Rel frequently combines with other related proteins (NF-KAPPA B, I-kappa B, relA) to form heterodimers that regulate transcription. Rearrangement or overexpression of c-rel can cause tumorigenesis. |
Preferred term | Proto-Oncogene Proteins c-rel |
Entry term(s) |
Protein, c-rel Proteins, c-rel Proto Oncogene Products c rel Proto Oncogene Protein c rel Proto Oncogene Proteins c rel Proto Oncogene Proteins rel Proto-Oncogene Products c-rel Proto-Oncogene Protein c-rel Proto-Oncogene Proteins rel Proto-Oncogene Proteins, rel c rel Protein c rel Proteins c-rel Protein c-rel Proteins c-rel, Proto-Oncogene Products c-rel, Proto-Oncogene Protein c-rel, Proto-Oncogene Proteins c-rel, p68 p68 c rel p68 c-rel p68(c-rel) rel Proto Oncogene Product p68 rel Proto Oncogene Proteins rel Proto-Oncogene Product p68 rel Proto-Oncogene Proteins |
We want your feedback on the new DeCS / MeSH website
We invite you to complete a survey that will take no more than 3 minutes.
Go to survey